Drug pricing reform talks with US government lack clarity, industry executives say

June 10, 2025 11:03 AM PDT | By EODHD

Google News:

Drug pricing reform talks with US government lack clarity, industry executives say — Image source: Kalkine Media

Recent News

DoubleVerify Sees Update in Digital Ad Tech Sector Russell 1000

Pagaya Technologies PGY Gains Support Nasdaq Index Stocks Watch

Oceaneering International OII Sees Institutional Growth on NYSE Compos...

GAMMA Expands Stake in Valvoline Inc Amid Market Movements S&P 500

By Bhanvi Satija and Christy Santhosh (Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday. President Donald Trump issued an executive order last month directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "most favored nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S.

to set prices for their products at the lowest price paid by other high-income countries. Lilly's chief financial officer, Lucas Montarce, said that it was not clear when a resolution on the pricing reform would be achieved. "It's hard to make any assumption about when, but they haven't shared with us any details at this time," said Montarce at the Goldman Sachs' Healthcare Conference. On Monday, Pfizer's chief executive Albert Bourla had said that the meetings with the Trump administration were focused on high-level ideas and not "digging into the substance." "Conversations are ongoing. No clarity yet on where it's going to go," said Merck's CEO Robert Davis.

Davis added that Merck has discussed how to share the cost of drug innovation, both in the United States and other countries, with the administration. "But how does that all translate into an actionable plan in the near term? There's still a lot of dialog happening, so that's not as clear," he said. Lilly and Merck executives said that any pricing reforms would require regulatory changes or government-to-government actions. AbbVie's CEO also said that there was a "long way to go" before an agreement would be reached on the pricing reform. (Reporting by Bhanvi Satija, Christy Santhosh and Kamal Choudhury in Bengaluru; Editing by Alan Barona) View Comments

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.